CN108431002A - 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途 - Google Patents
取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途 Download PDFInfo
- Publication number
- CN108431002A CN108431002A CN201680071166.XA CN201680071166A CN108431002A CN 108431002 A CN108431002 A CN 108431002A CN 201680071166 A CN201680071166 A CN 201680071166A CN 108431002 A CN108431002 A CN 108431002A
- Authority
- CN
- China
- Prior art keywords
- bases
- pyridine
- phenyl
- pyrazolos
- formic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)C1=CCCC(C)C1* Chemical compound CC(C)C1=CCCC(C)C1* 0.000 description 12
- DXSGXEMMBLFIEK-UHFFFAOYSA-N C(CN1CCOCC1)C1CCNCC1 Chemical compound C(CN1CCOCC1)C1CCNCC1 DXSGXEMMBLFIEK-UHFFFAOYSA-N 0.000 description 1
- YZXVYUZDVBWITQ-UHFFFAOYSA-N C1CC2NC2C1 Chemical compound C1CC2NC2C1 YZXVYUZDVBWITQ-UHFFFAOYSA-N 0.000 description 1
- VCGWZGPOYCFJEM-UHFFFAOYSA-O CC(C(c(c(-c(cn1)ccc1Cl)c1)c([NH2+]C2CCCCC2)nc1C(C)=O)=N)=C Chemical compound CC(C(c(c(-c(cn1)ccc1Cl)c1)c([NH2+]C2CCCCC2)nc1C(C)=O)=N)=C VCGWZGPOYCFJEM-UHFFFAOYSA-O 0.000 description 1
- FPUWCTBTBPMHQT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1(COC)O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(COC)O)=O FPUWCTBTBPMHQT-UHFFFAOYSA-N 0.000 description 1
- VZZTXMPAZZZOFX-UHFFFAOYSA-N CC(C)(C)[n]1nc(C2CCC2)cc1N Chemical compound CC(C)(C)[n]1nc(C2CCC2)cc1N VZZTXMPAZZZOFX-UHFFFAOYSA-N 0.000 description 1
- RTSDZHHMBYELFK-UHFFFAOYSA-N CC(C)C(c(c(-c1ccc(N2CC(C)OC(C)C2)nc1)c1)c(NC2CCCCC2)nc1C(O)=O)=N Chemical compound CC(C)C(c(c(-c1ccc(N2CC(C)OC(C)C2)nc1)c1)c(NC2CCCCC2)nc1C(O)=O)=N RTSDZHHMBYELFK-UHFFFAOYSA-N 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N CC(C)OC(Cl)=O Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- CBALEIWGGGNYOM-UHFFFAOYSA-N CC(c(c(N(CC1)CCC1OC)c1)c(Nc2ccccc2)nc1C(O)=O)=N Chemical compound CC(c(c(N(CC1)CCC1OC)c1)c(Nc2ccccc2)nc1C(O)=O)=N CBALEIWGGGNYOM-UHFFFAOYSA-N 0.000 description 1
- WSCDAAYKTGKSQO-ZULCIFJBSA-N CCC(Cc1ccccc1)c1nc(C(O)=O)cc(N(CC[C@@H]23)CC2=CCN3C(OC(C)C)=O)c1/C(/C1CCC1)=N\C Chemical compound CCC(Cc1ccccc1)c1nc(C(O)=O)cc(N(CC[C@@H]23)CC2=CCN3C(OC(C)C)=O)c1/C(/C1CCC1)=N\C WSCDAAYKTGKSQO-ZULCIFJBSA-N 0.000 description 1
- INCSIEJPHTYOTD-OLFWJLLRSA-N CCCC(C)/C(/c(c(N1CC(C)(CO)CCC1)c1)c(C)nc1C(O)=O)=N/NC1=CCCC=C1 Chemical compound CCCC(C)/C(/c(c(N1CC(C)(CO)CCC1)c1)c(C)nc1C(O)=O)=N/NC1=CCCC=C1 INCSIEJPHTYOTD-OLFWJLLRSA-N 0.000 description 1
- GOPOQJMWAJLQGI-UHFFFAOYSA-N CCCCCc(c(c(N1CCC(CCN2CCOCC2)CC1)c1)c2nc1C(O)=O)n[n]2-c1ccccc1 Chemical compound CCCCCc(c(c(N1CCC(CCN2CCOCC2)CC1)c1)c2nc1C(O)=O)n[n]2-c1ccccc1 GOPOQJMWAJLQGI-UHFFFAOYSA-N 0.000 description 1
- YUVDTVLADSKZHN-UHFFFAOYSA-N CCOC(c1cc(-c(cc2)ccc2C(N(C2)CC2N(C)C)=O)c2c(OC(C)C)n[n](C3CCCCC3)c2n1)=O Chemical compound CCOC(c1cc(-c(cc2)ccc2C(N(C2)CC2N(C)C)=O)c2c(OC(C)C)n[n](C3CCCCC3)c2n1)=O YUVDTVLADSKZHN-UHFFFAOYSA-N 0.000 description 1
- YPSRHLLNHZEZFE-UHFFFAOYSA-N CCOC(c1cc(-c(cc2)ccc2C(O)=O)c2c(OC(C)C)n[n](C3CCCCC3)c2n1)=O Chemical compound CCOC(c1cc(-c(cc2)ccc2C(O)=O)c2c(OC(C)C)n[n](C3CCCCC3)c2n1)=O YPSRHLLNHZEZFE-UHFFFAOYSA-N 0.000 description 1
- QVIAQMGZDZHJFK-UHFFFAOYSA-N CCOC(c1cc(N(CC2)CCC2OC)c(C(C(C)C)=N)c(N)n1)=O Chemical compound CCOC(c1cc(N(CC2)CCC2OC)c(C(C(C)C)=N)c(N)n1)=O QVIAQMGZDZHJFK-UHFFFAOYSA-N 0.000 description 1
- ICTPZGOOHDBQKP-UHFFFAOYSA-N CCOC(c1nc(Nc2cc(C)ccc2)c(C(C(C)C)=N)c(N2CC(CNC3)C3C2)c1)=O Chemical compound CCOC(c1nc(Nc2cc(C)ccc2)c(C(C(C)C)=N)c(N2CC(CNC3)C3C2)c1)=O ICTPZGOOHDBQKP-UHFFFAOYSA-N 0.000 description 1
- UUSZHBSIXIKKQX-UHFFFAOYSA-N CCOC(c1nc(Nc2cc(F)ncc2)c(C(C(C)C)=N)c(N(CC2)CCC2OC)c1)=O Chemical compound CCOC(c1nc(Nc2cc(F)ncc2)c(C(C(C)C)=N)c(N(CC2)CCC2OC)c1)=O UUSZHBSIXIKKQX-UHFFFAOYSA-N 0.000 description 1
- MWAWKBUABPKOQX-UHFFFAOYSA-N CCOC(c1nc(Nc2ccccc2)c(C(C)=N)c(N(CC2)CCC2O)c1)=O Chemical compound CCOC(c1nc(Nc2ccccc2)c(C(C)=N)c(N(CC2)CCC2O)c1)=O MWAWKBUABPKOQX-UHFFFAOYSA-N 0.000 description 1
- FZKXVCJUUMHYDD-UHFFFAOYSA-O CCOC(c1nc([NH2+]C2CCCCC2)c(C(OC(C)C)=N)c(-c(cc2)ccc2C(O)=O)c1)=O Chemical compound CCOC(c1nc([NH2+]C2CCCCC2)c(C(OC(C)C)=N)c(-c(cc2)ccc2C(O)=O)c1)=O FZKXVCJUUMHYDD-UHFFFAOYSA-O 0.000 description 1
- DKMFOHXYIGRKGR-UHFFFAOYSA-O CCOC(c1nc([NH2+]c2cc(C)ccc2)c(C(C(C)C)=N)c(N2CC(CN(C3)C(OC(C)(C)C)=O)C3C2)c1)=O Chemical compound CCOC(c1nc([NH2+]c2cc(C)ccc2)c(C(C(C)C)=N)c(N2CC(CN(C3)C(OC(C)(C)C)=O)C3C2)c1)=O DKMFOHXYIGRKGR-UHFFFAOYSA-O 0.000 description 1
- QZLXLLNSCGRNKC-UHFFFAOYSA-N COC(c1cc(N2CCC3(CCNCC3)CC2)c(c(C2CCC2)n[n]2-c(cc3)ccc3F)c2n1)=O Chemical compound COC(c1cc(N2CCC3(CCNCC3)CC2)c(c(C2CCC2)n[n]2-c(cc3)ccc3F)c2n1)=O QZLXLLNSCGRNKC-UHFFFAOYSA-N 0.000 description 1
- YHBKECYKQMGJMD-UHFFFAOYSA-N COCC1(CCNCC1)O Chemical compound COCC1(CCNCC1)O YHBKECYKQMGJMD-UHFFFAOYSA-N 0.000 description 1
- HNVIQLPOGUDBSU-LWOQYNTDSA-N C[C@H]1OC(C)CNC1 Chemical compound C[C@H]1OC(C)CNC1 HNVIQLPOGUDBSU-LWOQYNTDSA-N 0.000 description 1
- FITVGIIWAUABBY-UHFFFAOYSA-N Cc(c(c1nc(C(OC)=O)c2)c2-c(cc2)ccc2N(C)C2CCC2)n[n]1-c1ccccc1 Chemical compound Cc(c(c1nc(C(OC)=O)c2)c2-c(cc2)ccc2N(C)C2CCC2)n[n]1-c1ccccc1 FITVGIIWAUABBY-UHFFFAOYSA-N 0.000 description 1
- JMDPBPFSLZCRFC-UHFFFAOYSA-N Cc(c(c1nc(C(OC)=O)c2)c2-c(cc2)ccc2NC2CCC2)n[n]1-c1ccccc1 Chemical compound Cc(c(c1nc(C(OC)=O)c2)c2-c(cc2)ccc2NC2CCC2)n[n]1-c1ccccc1 JMDPBPFSLZCRFC-UHFFFAOYSA-N 0.000 description 1
- FOCJXECLIBAZSA-UHFFFAOYSA-N N#CCC(C1CCCC1)=O Chemical compound N#CCC(C1CCCC1)=O FOCJXECLIBAZSA-UHFFFAOYSA-N 0.000 description 1
- PVTIXAJOZAXDMH-UHFFFAOYSA-N N=C(C1CCC1)c(c(OCC1CCOCC1)c1)c(Nc2ccccc2)nc1C(O)=O Chemical compound N=C(C1CCC1)c(c(OCC1CCOCC1)c1)c(Nc2ccccc2)nc1C(O)=O PVTIXAJOZAXDMH-UHFFFAOYSA-N 0.000 description 1
- GFOMKMRCYBGHRS-QUCCMNQESA-N NC1(CC1)C(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(N(CC2)C[C@@H]3[C@H]2NCC3)c1)=O Chemical compound NC1(CC1)C(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(N(CC2)C[C@@H]3[C@H]2NCC3)c1)=O GFOMKMRCYBGHRS-QUCCMNQESA-N 0.000 description 1
- YNOGYQAEJGADFJ-YFKPBYRVSA-N NC[C@H]1OCCC1 Chemical compound NC[C@H]1OCCC1 YNOGYQAEJGADFJ-YFKPBYRVSA-N 0.000 description 1
- NHVRUCCVUJWWPF-UHFFFAOYSA-N NNc1cccc(N2CCOCC2)c1 Chemical compound NNc1cccc(N2CCOCC2)c1 NHVRUCCVUJWWPF-UHFFFAOYSA-N 0.000 description 1
- ZJWLMZURLIHVHE-UHFFFAOYSA-N Nc1cccc(N2CCOCC2)c1 Chemical compound Nc1cccc(N2CCOCC2)c1 ZJWLMZURLIHVHE-UHFFFAOYSA-N 0.000 description 1
- SCKYDIHYLGMPNJ-UHFFFAOYSA-N OC(c1cc(N(CC2)CCC2C=O)c(c(C2CCC2)n[n]2-c3ccccc3)c2n1)=O Chemical compound OC(c1cc(N(CC2)CCC2C=O)c(c(C2CCC2)n[n]2-c3ccccc3)c2n1)=O SCKYDIHYLGMPNJ-UHFFFAOYSA-N 0.000 description 1
- HVTRMFLGXXYROK-UHFFFAOYSA-N OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(Cl)c1)=O Chemical compound OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(Cl)c1)=O HVTRMFLGXXYROK-UHFFFAOYSA-N 0.000 description 1
- UYARKADPHYZWBL-UHFFFAOYSA-N OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(Cl)c1)=[O-] Chemical compound OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(Cl)c1)=[O-] UYARKADPHYZWBL-UHFFFAOYSA-N 0.000 description 1
- NHLMMNBVQHNFAO-INIZCTEOSA-N OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(NC[C@H]2OCCC2)c1)=O Chemical compound OC(c1nc([n](-c2ccccc2)nc2C3CCC3)c2c(NC[C@H]2OCCC2)c1)=O NHLMMNBVQHNFAO-INIZCTEOSA-N 0.000 description 1
- WIOCJAPOSLEVAM-UHFFFAOYSA-N OCC(CC1)CCN1c1c(c(C2CCC2)n[n]2-c3ccccc3)c2nc(C(O)=O)c1 Chemical compound OCC(CC1)CCN1c1c(c(C2CCC2)n[n]2-c3ccccc3)c2nc(C(O)=O)c1 WIOCJAPOSLEVAM-UHFFFAOYSA-N 0.000 description 1
- YSNVSVCWTBLLRW-UHFFFAOYSA-N OCC1CCOCC1 Chemical compound OCC1CCOCC1 YSNVSVCWTBLLRW-UHFFFAOYSA-N 0.000 description 1
- UOQZPQIRCQUSAJ-UHFFFAOYSA-N O[BH2-]c1cc(F)ncc1 Chemical compound O[BH2-]c1cc(F)ncc1 UOQZPQIRCQUSAJ-UHFFFAOYSA-N 0.000 description 1
- XOONUEZBABVLCZ-ULUSZKPHSA-N O[C@H](C1)C11CNCCC1 Chemical compound O[C@H](C1)C11CNCCC1 XOONUEZBABVLCZ-ULUSZKPHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239475P | 2015-10-09 | 2015-10-09 | |
| US62/239475 | 2015-10-09 | ||
| PCT/IB2016/056028 WO2017060873A1 (en) | 2015-10-09 | 2016-10-07 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108431002A true CN108431002A (zh) | 2018-08-21 |
Family
ID=57200057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680071166.XA Pending CN108431002A (zh) | 2015-10-09 | 2016-10-07 | 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9796711B2 (https=) |
| EP (1) | EP3359539A1 (https=) |
| JP (1) | JP2018530557A (https=) |
| CN (1) | CN108431002A (https=) |
| AU (1) | AU2016333855A1 (https=) |
| BR (1) | BR112018007145A2 (https=) |
| CA (1) | CA3001094A1 (https=) |
| MX (1) | MX2018004364A (https=) |
| TW (1) | TW201735769A (https=) |
| WO (1) | WO2017060873A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| EP3686196B1 (en) * | 2017-09-20 | 2024-06-12 | Hangzhou Innogate Pharma Co., Ltd. | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020178316A1 (en) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | 5- or 7-azaindazoles as beta-lactamase inhibitors |
| GB201905711D0 (en) | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| KR20240168948A (ko) * | 2022-02-08 | 2024-12-02 | 이턴 바이오파마 (상하이) 코., 엘티디. | 바이사이클릭 헤테로아릴 화합물들 및 이의 용도들 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197911A1 (en) * | 2004-08-20 | 2009-08-06 | Ingrid Gunda Georg | Lonidamine analogues and treatment of polycystic kidney disease |
| WO2014081820A1 (en) * | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule cftr correctors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| CA2569402A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| BRPI0708615A2 (pt) * | 2006-03-07 | 2011-06-07 | Array Biopharma Inc | compostos de pirazol heterobicìclicos e métodos de uso |
| JP5686596B2 (ja) | 2007-05-25 | 2015-03-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| CN102224141B (zh) | 2008-10-23 | 2014-10-08 | 沃泰克斯药物股份有限公司 | N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式 |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| KR101886459B1 (ko) | 2010-10-08 | 2018-08-07 | 니발리스 테라퓨틱스, 인코포레이티드 | S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물 |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) * | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| AU2012312520A1 (en) | 2011-09-20 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by PLUNC proteins |
| WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| PT3030568T (pt) | 2013-08-08 | 2018-12-24 | Galapagos Nv | Tieno[2,3-c]piranos como moduladores de cftr |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US9745292B2 (en) | 2014-03-13 | 2017-08-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| MX2017005663A (es) | 2014-10-31 | 2018-03-01 | Abbvie Sarl | Tetrahidropiranos sustituidos y metodo de uso. |
| DK3212189T3 (da) | 2014-10-31 | 2020-10-26 | Abbvie Overseas Sarl | Substituerede chromaner og fremgangsmåde til anvendelse deraf |
-
2016
- 2016-10-07 TW TW105132657A patent/TW201735769A/zh unknown
- 2016-10-07 JP JP2018517362A patent/JP2018530557A/ja active Pending
- 2016-10-07 EP EP16785567.5A patent/EP3359539A1/en not_active Withdrawn
- 2016-10-07 US US15/287,922 patent/US9796711B2/en not_active Expired - Fee Related
- 2016-10-07 WO PCT/IB2016/056028 patent/WO2017060873A1/en not_active Ceased
- 2016-10-07 AU AU2016333855A patent/AU2016333855A1/en not_active Abandoned
- 2016-10-07 MX MX2018004364A patent/MX2018004364A/es unknown
- 2016-10-07 CA CA3001094A patent/CA3001094A1/en not_active Abandoned
- 2016-10-07 CN CN201680071166.XA patent/CN108431002A/zh active Pending
- 2016-10-07 BR BR112018007145A patent/BR112018007145A2/pt not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197911A1 (en) * | 2004-08-20 | 2009-08-06 | Ingrid Gunda Georg | Lonidamine analogues and treatment of polycystic kidney disease |
| WO2014081820A1 (en) * | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Small molecule cftr correctors |
Non-Patent Citations (3)
| Title |
|---|
| VALENTIN A.CHEBANOV ET AL.: "Cyclocondensation reactions of 5-aminopyrazoles, pyruvic acids and aldehydes. Multicomponent approaches to pyrazolopyridines and related products", 《TETRAHEDRON》 * |
| 来源于AURORA FINE CHEMICALS等提供的产品目录: ""STN检索报告1"", 《数据库REGISTRY（在线）》 * |
| 王新颖 刘冬青: "囊性纤维化疾病调节剂的研究进展", 《天津化工》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201735769A (zh) | 2017-10-16 |
| CA3001094A1 (en) | 2017-04-13 |
| MX2018004364A (es) | 2018-08-16 |
| US20170101406A1 (en) | 2017-04-13 |
| JP2018530557A (ja) | 2018-10-18 |
| WO2017060873A1 (en) | 2017-04-13 |
| BR112018007145A2 (pt) | 2018-11-06 |
| EP3359539A1 (en) | 2018-08-15 |
| AU2016333855A1 (en) | 2018-04-26 |
| US9796711B2 (en) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108513574B (zh) | N-磺酰化吡唑并[3，4-b]吡啶-6-甲酰胺和使用方法 | |
| CN108431002A (zh) | 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途 | |
| US10988478B1 (en) | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | |
| CN103987707B (zh) | 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法 | |
| CN103429585B (zh) | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物 | |
| CN109970743B (zh) | 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物 | |
| KR20230173234A (ko) | 인다졸계 화합물 및 관련된 사용 방법 | |
| CN112105357A (zh) | 药用6,5杂双环衍生物 | |
| CN114907338B (zh) | 含氮多环稠环类化合物，其药物组合物、制备方法和用途 | |
| CN105246890A (zh) | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 | |
| CN107849044A (zh) | 作为ddr1抑制剂的三氮杂‑螺癸酮类化合物 | |
| TW202510868A (zh) | 新穎吡唑并吡啶衍生物 | |
| WO2025077671A1 (zh) | 多取代芳基类衍生物及其制备方法和用途 | |
| HK40125896A (zh) | 新颖苯并咪唑衍生物 | |
| JP2025527747A (ja) | 置換ピリドピリミジノン | |
| CN115151256A (zh) | 用于治疗与dux4表达相关的疾病的新化合物 | |
| HK40010369B (zh) | 为jak抑制剂的5-氯-2-二氟甲氧基苯基吡唑并嘧啶化合物 | |
| HK1259623B (zh) | 作爲irak4调节剂的吡唑并[1,5a]嘧啶衍生物 | |
| HK40012363A (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| HK1251572B (zh) | 作为ddr1抑制剂的三氮杂-螺癸酮类化合物 | |
| HK1245783A1 (en) | Triazolopyridine compounds and methods of use thereof | |
| HK1233621A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
| HK1191938B (en) | Indazolyl triazole derivatives as irak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180821 |
|
| WD01 | Invention patent application deemed withdrawn after publication |